Edwards Lifesciences (EW) Experiences Rubust Heart Valve Sales, Analyst Sees Upside
Tweet Send to a FriendGet Alerts EW Hot Sheet
Price: $65.53 -0.29%
Rating Summary:
11 Buy, 14 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
11 Buy, 14 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade EW Now!
Jefferies today reiterated a Buy rating on Edwards Lifesciences (NYSE: EW) and raised its price target to $114.00 (from $100.00). The increased price target accounts for solid Q4 results highlighted by strong US Sapien transcatheter heart valve sales.
"While we have tempered our total 2013 US Sapien estimate based solely on stocking/consignment, our commercial unit forecasts move higher as implants are tracking ahead of expectations," said analyst Raj Denhoy.
"Specifically, we now model only marginal net sales contribution for the year from stocking valves which will transition from a tailwind to a headwind over the course of the year as centers move to consignment . . . Importantly, however, based on the 4Q momentum and our physician checks, we have increased our commercial Sapien sales forecast to $361 million from $323 million," added the analyst.
Jefferies models total U.S. Saipien sales of $397 million, compared to management guidance of $390 to $440 million.
For an analyst ratings summary and ratings history on Edwards Lifesciences (NYSE: EW) click here. For more ratings news on Edwards Lifesciences click here.
Shares of Edwards Lifesciences closed at $93.06 yesterday, with a 52 week range of $67.86-$110.79.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
"While we have tempered our total 2013 US Sapien estimate based solely on stocking/consignment, our commercial unit forecasts move higher as implants are tracking ahead of expectations," said analyst Raj Denhoy.
"Specifically, we now model only marginal net sales contribution for the year from stocking valves which will transition from a tailwind to a headwind over the course of the year as centers move to consignment . . . Importantly, however, based on the 4Q momentum and our physician checks, we have increased our commercial Sapien sales forecast to $361 million from $323 million," added the analyst.
Jefferies models total U.S. Saipien sales of $397 million, compared to management guidance of $390 to $440 million.
For an analyst ratings summary and ratings history on Edwards Lifesciences (NYSE: EW) click here. For more ratings news on Edwards Lifesciences click here.
Shares of Edwards Lifesciences closed at $93.06 yesterday, with a 52 week range of $67.86-$110.79.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Dollar Tree (DLTR) Beats But Looks Stretched - Jefferies
- Imperial Capital Boosts Price Target on Dick's (DKS); 'Best-of-Breed'
- Jefferies Lifts Numbers on Diana Shipping (DSX) Post Q1
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeRelated Entities
Jefferies & Co
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
